@article {1364502,
	title = {Oral acetazolamide after Boston keratoprosthesis in Stevens-Johnson syndrome},
	journal = {BMC Res Notes},
	volume = {5},
	year = {2012},
	month = {2012 Apr 30},
	pages = {205},
	abstract = {BACKGROUND: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a rare but severe and sometimes fatal condition associated with exposure to medications; sulfamethoxazole is among the most common causes. We sought to address the safety of acetazolamide, a chemically related compound, in patients with prior SJS/TEN and glaucoma. A retrospective case series is described of patients at the Massachusetts Eye and Ear Infirmary who underwent keratoprosthesis surgery for corneal blindness from SJS/TEN, and later required oral acetazolamide for elevated intraocular pressure. FINDINGS: Over the last 10 years, 17 patients with SJS/TEN received a Boston keratoprosthesis. Of these, 11 developed elevated intraocular pressure that required administration of oral acetazolamide. One of 11 developed a mild allergic reaction, but no patient experienced a recurrence of SJS/TEN or any severe adverse reaction. CONCLUSION: Although an increase in the rate of recurrent SJS/TEN due to oral acetazolamide would not necessarily be apparent after treating only 11 patients, in our series, acetazolamide administration was well tolerated without serious sequela.},
	keywords = {Acetazolamide, Administration, Oral, Adolescent, Adult, Boston, Carbonic Anhydrase Inhibitors, Cornea, Female, Glaucoma, Humans, Intraocular Pressure, Male, Middle Aged, Polymethyl Methacrylate, Prostheses and Implants, Retrospective Studies, Stevens-Johnson Syndrome, Titanium},
	issn = {1756-0500},
	doi = {10.1186/1756-0500-5-205},
	author = {Kumar, Radhika and Dohlman, Claes H and Chodosh, James}
}
